Imugene’s Azer-cel Therapy Shows Encouraging Progress in Phase 1b Trial

Highlights

• Azer-cel therapy demonstrates strong clinical activity in blood cancer treatment
• Expanded trial now includes wider range of lymphoma subtypes
• First Australian patient shows complete cancer clearance

Imugene Ltd (ASX:IMU) has shared new clinical updates from its ongoing Phase 1b trial of azer-cel (azercabtagene zapreleucel), an allogeneic CAR T-cell therapy developed for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). While Imugene is not part of the ASX 100 companies, its advancements in next-generation cancer therapies continue to attract significant attention in the biotechnology sector.

Azer-cel is designed as an “off-the-shelf” treatment option, aiming to overcome the limitations of currently approved autologous CAR T therapies, such as manufacturing delays, access restrictions, and geographic challenges.

Expanding Patient Scope and Clinical Reach

The trial has recently broadened to include CAR T-naïve patients with other difficult-to-treat non-Hodgkin lymphoma (NHL) subtypes. These include primary central nervous system lymphoma (PCNSL), chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), marginal zone lymphoma (MZL), Waldenström macroglobulinemia (WM), and follicular lymphoma (FL).

Notably, the first patient treated in Australia achieved a complete response, underscoring the potential of azer-cel to address urgent unmet needs. Trials are actively enrolling across multiple clinical sites in the United States, with Australian expansion underway.

Science Behind Azer-cel and IL-2 Combination

The therapy is being tested alongside lymphodepletion (LD) and interleukin 2 (IL-2). IL-2 plays a vital role in immune regulation, helping T cells survive and perform more effectively in detecting and attacking cancer cells. The combination is showing a manageable safety profile while delivering durable responses in patients who had previously exhausted conventional treatment options.

This research holds significant implications for blood cancer treatment, particularly in cases where relapse remains common despite existing CAR T-cell therapy availability. With further updates expected as more patient data emerges, Imugene’s progress continues to be closely monitored within the medical and investor communities.